You are here

  • Home
  • Archive
  • Volume 4, Issue 1
  • Advances in immunotherapeutic strategies for colorectal cancer commentary on: tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients by Halama et al

Article info

Article menu

Download PDFPDF

Commentary
Advances in immunotherapeutic strategies for colorectal cancer commentary on: tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients by Halama et al

Authors

  • Dustin A. Deming Division of Hematology and Oncology, Department of MedicineUniversity of Wisconsin-Madison Madison WI USA University of Wisconsin Carbone Cancer Center Madison WI USA McArdle Laboratory for Cancer Research, Department of OncologyUniversity of Wisconsin-Madison Madison WI USA William S Middleton Memorial Veterans Hospital Madison WI USA PubMed articlesGoogle scholar articles

Citation

Deming DA
Advances in immunotherapeutic strategies for colorectal cancer commentary on: tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients by Halama et al
Journal for ImmunoTherapy of Cancer 2016;4:93. doi: 10.1186/s40425-016-0197-y
Online issue publication 
December 20, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.